Compounds > ozocerite
Page last updated: 2024-11-13

ozocerite

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID21596125
CHEMBL ID450831
SCHEMBL ID168229
MeSH IDM0074182

Synonyms (13)

Synonym
ozocerite
ozokerite
CHEMBL450831
unii-q1ls2ujo3a
waxes, ceresin
einecs 232-290-1
ceresin
waxes, ozocerite
8001-75-0
q1ls2ujo3a ,
SCHEMBL168229
cerin
(2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID357959Cytotoxicity against human T cells assessed as cell viability at IC50 after 24 hrs by MTT assay2001Journal of natural products, Oct, Volume: 64, Issue:10
Synthetic secofriedelane and friedelane derivatives as inhibitors of human lymphocyte proliferation and growth of human cancer cell lines in vitro.
AID357957Inhibition of PHA-induced human T cell proliferation after 24 hrs by MTT assay2001Journal of natural products, Oct, Volume: 64, Issue:10
Synthetic secofriedelane and friedelane derivatives as inhibitors of human lymphocyte proliferation and growth of human cancer cell lines in vitro.
AID357953Cytotoxicity against human TK10 cells by SRB assay2001Journal of natural products, Oct, Volume: 64, Issue:10
Synthetic secofriedelane and friedelane derivatives as inhibitors of human lymphocyte proliferation and growth of human cancer cell lines in vitro.
AID357954Cytotoxicity against human UACC62 cells by SRB assay2001Journal of natural products, Oct, Volume: 64, Issue:10
Synthetic secofriedelane and friedelane derivatives as inhibitors of human lymphocyte proliferation and growth of human cancer cell lines in vitro.
AID357952Cytotoxicity against human MCF7 cells by SRB assay2001Journal of natural products, Oct, Volume: 64, Issue:10
Synthetic secofriedelane and friedelane derivatives as inhibitors of human lymphocyte proliferation and growth of human cancer cell lines in vitro.
AID357955Cytotoxicity against human NCI-H460 cells by SRB assay2001Journal of natural products, Oct, Volume: 64, Issue:10
Synthetic secofriedelane and friedelane derivatives as inhibitors of human lymphocyte proliferation and growth of human cancer cell lines in vitro.
AID357956Cytotoxicity against human SF268 cells by SRB assay2001Journal of natural products, Oct, Volume: 64, Issue:10
Synthetic secofriedelane and friedelane derivatives as inhibitors of human lymphocyte proliferation and growth of human cancer cell lines in vitro.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (70.37)18.7374
1990's0 (0.00)18.2507
2000's4 (14.81)29.6817
2010's4 (14.81)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.69 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.19 (4.65)
Search Engine Demand Index56.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.44%)6.00%
Case Studies1 (2.44%)4.05%
Observational0 (0.00%)0.25%
Other39 (95.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
benzene
[no description available]		1.9210aromatic annulene;
benzenes;
volatile organic compound		carcinogenic agent;
environmental contaminant;
non-polar solvent
tetracosane
tetracosane: a pure alkane compound. tetracosane : A straight-chain alkane containing 24 carbon atoms.		2.0310long-chain alkaneplant metabolite;
volatile oil component
octylmethoxycinnamate
octylmethoxycinnamate: a sunscreen used for prevention of DNA photodamage		2.0510cinnamate ester
delphinidin
Paraffin: A mixture of solid hydrocarbons obtained from petroleum. It has a wide range of uses including as a stiffening agent in ointments, as a lubricant, and as a topical anti-inflammatory. It is also commonly used as an embedding material in histology.. delphinidin chloride : An anthocyanidin chloride that has delphinidin as the cationic counterpart.		2.4320anthocyanidin chloride
friedelin
3-friedelanone: from the stem bark of Irvingia gabonensis; structure in first source. friedelin : A pentacyclic triterpenoid that is perhydropicene which is substituted by an oxo group at position 3 and by methyl groups at the 4, 4a, 6b, 8a, 11, 11, 12b, and 14a-positions (the 4R,4aS,6aS,6bR,8aR,12aR,12bS,14aS,14bS-enantiomer). It is the major triterpenoid constituent of cork.		210cyclic terpene ketone;
pentacyclic triterpenoid		anti-inflammatory drug;
antipyretic;
non-narcotic analgesic;
plant metabolite
friedelinol
friedelinol: isolated from seeds of Aster auriculatus Franch; structure given in first source; RN given refers to friedelanol (friedelinol), the (3alpha)-isomer		210
rosin
rosin: Resin from plant. Do not confuse with the specific compound: 3-phenyl-2-propenyl-(E)-beta-D-glucopyranoside, also know as rosin.		2.0210
cyclosporine
ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF		210homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
glyceryl behenate
1-behenoylglycerol : A fatty acid ester resulting from the formal condensation of the hydroxy group at position-1 of glycerol with the carboxy group of docosanoic acid.		2.05101-monoglyceride;
fatty acid ester		antineoplastic agent;
plant metabolite
clay
Clay: A naturally-occurring rock or soil constituent characterized by particles with a diameter of less than 0.005 mm. It is composed primarily of hydrous aluminum silicates, trace amounts of metal OXIDES, and organic matter.		1.9610
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms, Brain
[description not available]		0210
Breast Cancer
[description not available]		0210
Cancer of Kidney
[description not available]		0210
Cancer of Lung
[description not available]		0210
Malignant Melanoma
[description not available]		0210
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		0210
Breast Neoplasms
Tumors or cancer of the human BREAST.		0210
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		0210
Lung Neoplasms
Tumors or cancer of the LUNG.		0210
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		0210
Allergic Contact Dermatitis
[description not available]		02.0710
Cheilitis
Inflammation of the lips. It is of various etiologies and degrees of pathology.		02.0710
Dermatitis, Allergic Contact
A contact dermatitis due to allergic sensitization to various substances. These substances subsequently produce inflammatory reactions in the skin of those who have acquired hypersensitivity to them as a result of prior exposure.		02.0710
Gastroduodenal Ulcer
[description not available]		01.9310
Peptic Ulcer
Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).		01.9310
Experimental Lung Inflammation
Inflammation of any part, segment or lobe, of the lung parenchyma.		01.9310
Pneumonia
Infection of the lung often accompanied by inflammation.		06.9310
Craniofacial Pain Syndromes
[description not available]		01.9310
Endarteritis
Inflammation of the inner endothelial lining (TUNICA INTIMA) of an artery.		02.3420
Nerve Root Avulsion
[description not available]		01.9310
Polyradiculitis
[description not available]		01.9310
Polyradiculopathy
Disease or injury involving multiple SPINAL NERVE ROOTS. Polyradiculitis refers to inflammation of multiple spinal nerve roots.		01.9310
Radiculopathy
Disease involving a spinal nerve root (see SPINAL NERVE ROOTS) which may result from compression related to INTERVERTEBRAL DISK DISPLACEMENT; SPINAL CORD INJURIES; SPINAL DISEASES; and other conditions. Clinical manifestations include radicular pain, weakness, and sensory loss referable to structures innervated by the involved nerve root.		01.9310
Buerger Disease
[description not available]		01.9310
Injuries
Used with anatomic headings, animals, and sports for wounds and injuries. Excludes cell damage, for which pathology is used.		02.3420
Wounds and Injuries
Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.		02.3420
Disease
A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.		01.9210
Pus
[description not available]		01.9610
Wounds, Penetrating
Wounds caused by objects penetrating the skin.		01.9610
Chronic Illness
[description not available]		02.3620
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		02.3620
Gastritis
Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.		02.3620
Disease, Pulmonary
[description not available]		01.9510
Chest Injuries
[description not available]		01.9510
Pleural Diseases
Diseases involving the PLEURA.		01.9510
Lung Diseases
Pathological processes involving any part of the LUNG.		01.9510